NCT05658562 2026-02-13
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Tanabe Pharma Corporation
Phase 1/2 Active not recruiting
Tanabe Pharma Corporation
Case Comprehensive Cancer Center
ADC Therapeutics S.A.
Medical College of Wisconsin